Venom Composition and Therapeutic Applications

Venoms are complex mixtures of bioactive molecules, notably peptides and proteins, evolved to immobilise prey or deter predators. The composition of venoms varies widely between taxa and even among populations, reflecting evolutionary pressures and prey specificity. Major protein families include phospholipase A₂ enzymes, metalloproteases, serine proteases and three-finger toxins, each contributing to distinct pathologies such as neurotoxicity, coagulopathy and cytotoxicity. Advances in transcriptomics and proteomics have mapped thousands of venom components, revealing both dominant and low-abundance toxins whose roles are still being elucidated. Beyond their ecological function, venom constituents have inspired a range of therapeutic applications, from diagnostic reagents to novel drugs. Traditional plasma-derived antivenoms remain the mainstay of treatment, but next-generation approaches encompass recombinant monoclonal antibodies, small-molecule inhibitors and engineered toxin derivatives aimed at improving safety, specificity and accessibility. These innovations hold promise not only for more effective envenoming therapies but also for broader drug discovery in areas such as pain management, cardiovascular disease and oncology.

Research from Nature Portfolio

A recent study established a phage display pipeline to isolate and optimise human monoclonal antibodies that broadly neutralise long-chain α-neurotoxins from elapid snakes. The resulting recombinant antibody demonstrates unparalleled potency in vitro, neutralising multiple α-neurotoxins at low molar ratios, and offers complete protection in rodent models challenged with whole venoms from diverse species. This work exemplifies the shift towards fully defined, human-compatible biotherapeutics that may overcome limitations of conventional antivenoms, including batch variability and immunogenicity.

Research from all publishers

Emerging analyses of predatory venoms highlight the role of prey specificity in shaping toxin repertoires. A comprehensive review of prey-specialist snakes, cone snails and spiders underscores how restricted diets drive the evolution of highly potent, targeted venoms, offering templates for selective bioactive agents. Complementing this, a database collating proteomic profiles from over 130 snake species has detailed the relative abundance and diversity of eight principal toxin families, facilitating comparative studies and guiding antivenom design. On the therapeutic front, repurposing of varespladib—a small-molecule inhibitor of secreted phospholipase A₂—has shown broad-spectrum inhibition of venom PLA₂ activity at nanomolar concentrations and significant survival benefits in preclinical envenoming models, indicating its potential as an early intervention in resource-limited settings.

Venom Composition and Therapeutic Applications publication trend

The graph below shows the total number of articles in venom composition and therapeutic applications across all publications each year (not limited to Nature Index journals).

Technical terms

Monoclonal antibody: A uniform antibody produced by a single clone of cells, designed to target a specific toxin.

Phospholipase A₂ (PLA₂): An enzyme that hydrolyses phospholipids in cell membranes, commonly found in venom and contributing to toxicity.

Proteomics: The large-scale study of proteins, their structures and functions, often using mass spectrometry.

Neurotoxin: A toxin that disrupts the normal function of the nervous system, often by blocking synaptic transmission.

Metalloprotease: An enzyme requiring a metal ion cofactor that degrades extracellular matrix proteins and can cause haemorrhage.

References

1. Discovery and optimization of a broadly-neutralizing human monoclonal antibody against long-chain α-neurotoxins from snakes. Nature Communications (2023).
2. Prey specificity of predatory venoms. Biological Reviews (2024).
3. A Review and Database of Snake Venom Proteomes. Toxins (2017).
4. Varespladib (LY315920) Appears to Be a Potent, Broad-Spectrum, Inhibitor of Snake Venom Phospholipase A2 and a Possible Pre-Referral Treatment for Envenomation. Toxins (2016).